Body Dysmorphic Disorder Clinical Trial
Official title:
Neural Mechanisms of Perceptual Abnormalities and Their Malleability in Body Dysmorphic Disorder
A core symptom of body dysmorphic disorder (BDD) is perceptual distortions for appearance, which contributes to poor insight and delusionality, limits engagement in treatment, and puts individuals at risk for relapse. Results from this study will provide a comprehensive mechanistic model of brain, behavioral, and emotional contributors to abnormal perceptual processing, as well as how malleable it is with visual modulation techniques. This will lay the groundwork for next-step translational perceptual retraining approaches.
Individuals with body dysmorphic disorder (BDD) misperceive specific aspects of one's own appearance to be conspicuously flawed or defective, despite these being unnoticeable or appearing minuscule to others. With convictions of disfigurement and ugliness, individuals with BDD typically have poor insight or delusional beliefs, obsessive thoughts and compulsive behaviors, anxiety, and depression. These result in significant difficulties in functioning, depression, suicide attempts (25%), and psychiatric hospitalization (50%). Despite this, relatively few studies of the neurobiology, and few treatment studies, have been conducted. This underscores a critical need for research to identify novel targets for intervention based on a comprehensive understanding of the pathophysiological mechanisms. Neuropsychological, behavioral, and neurobiological research by investigators have uncovered mechanisms that may contribute to perceptual distortions, including prominent abnormalities in visual processing systems. These have contributed to a model of diminished global/holistic processing and enhanced local/detailed processing, attributed to "bottom-up" and "top-down" disturbances in perception. Using psychophysical experiments and novel visual modulation techniques, investigators have probed the brain's visual systems responsible for global and local processing and found early evidence that they may be modifiable in BDD. These techniques include a "top-down" attentional modulation and a "bottom-up" perceptual modulation strategy. Abnormal eye gaze and emotional arousal when viewing faces may further contribute to abnormal perception. Whether these brain and behavior abnormalities are directly linked to abnormal perception remains to be understood. Accordingly, this study will determine a) if abnormalities in neural activation and connectivity in BDD when viewing one's own appearance are directly associated with abnormalities in perceptual functioning; and b) if changes in neural activation and connectivity from these visual modulation strategies are linked to changes in perceptual functioning, thus representing potential biomarkers. Investigators will also determine how attentional systems, eye gaze behaviors and emotional arousal interact with brain functioning in visual systems, and with global and local perceptual functioning. Investigators will enroll participants with BDD, with subclinical BDD, and healthy controls who will undergo functional magnetic resonance imaging while viewing photographs of own, and others' faces. Investigators will obtain measures of global and local visual processing, emotional arousal while participants view own face, and eye gaze behaviors using eye tracking. To understand the malleability of global/local perception, and the neural mechanisms of these changes, investigators will determine whether repeated visual modulation using top-down and bottom-up strategies results in alterations of perceptual functioning and brain activity/connectivity, and relationships between them. Results will provide a comprehensive mechanistic model of abnormal visual information processing underlying the core symptom domain of misperceptions of appearance. This will lay the groundwork for next-step translational approaches. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02635152 -
Interpretation Bias Modification for Body Dysmorphic Disorder
|
N/A | |
Completed |
NCT03673046 -
Waitlist-Control Trial of Smartphone Cognitive Behavioral Therapy (CBT) for Body Dysmorphic Disorder (BDD)
|
N/A | |
Recruiting |
NCT05402475 -
Online Cognitive Behavioural Therapy Intervention for Body Dysmorphic Disorder
|
N/A | |
Withdrawn |
NCT02843451 -
Milk Thistle in Body Dysmorphic Disorder
|
Phase 2 | |
Completed |
NCT02010619 -
Internet Delivered CBT for Body Dysmorphic Disorder
|
N/A | |
Completed |
NCT00842309 -
D-Cycloserine Augmentation of Behavior Therapy for Individuals With Body Dysmorphic Disorder
|
Early Phase 1 | |
Completed |
NCT00245635 -
Fluoxetine in Pediatric Body Dysmorphic Disorder
|
Phase 4 | |
Completed |
NCT02808702 -
Brain Correlates of Self-Focused Processing
|
N/A | |
Completed |
NCT01002326 -
Cognitive-Behavioral Therapy for Pediatric Body Dysmorphic Disorder
|
N/A | |
Active, not recruiting |
NCT01075672 -
Outcomes of Cognitive Behavioral Therapy (CBT) Interventions Provided by Unlicensed Professionals
|
N/A | |
Completed |
NCT02671266 -
Oxytocin Administration in BDD and OCD
|
Phase 2 | |
Completed |
NCT01038128 -
An Open Label Trial of Memantine in the Treatment of Bulimia Nervosa and Body Dysmorphic Disorder
|
N/A | |
Completed |
NCT01398865 -
Escitalopram Neuroimaging Supplement
|
N/A | |
Completed |
NCT00265109 -
Effectiveness of Levetiracetam in the Treatment of Body Dysmorphic Disorder
|
Phase 4 | |
Completed |
NCT01453439 -
Cognitive-Behavioral Therapy and Supportive Psychotherapy for Body Dysmorphic Disorder
|
N/A | |
Completed |
NCT00871143 -
Cognitive Behaviour Therapy (CBT) for Body Dysmorphic Disorder (BDD)
|
N/A | |
Completed |
NCT00106223 -
Treatment Study Investigating New Cognitive Behavioral Therapy Treatment Manual for Body Dysmorphic Disorder
|
N/A | |
Active, not recruiting |
NCT00211809 -
CBT as an Adjunct to SRIs in the Treatment of BDD
|
Phase 4 |